• Media type: E-Article
  • Title: MAPK blockade, toxicities, pathogenesis and management
  • Contributor: Moreira, Alvaro; Lebbé, Céleste; Heinzerling, Lucie
  • Published: Ovid Technologies (Wolters Kluwer Health), 2021
  • Published in: Current Opinion in Oncology
  • Extent: 139-145
  • Language: English
  • DOI: 10.1097/cco.0000000000000710
  • ISSN: 1040-8746; 1531-703X
  • Keywords: Cancer Research ; Oncology
  • Abstract: <jats:sec> <jats:title>Purpose of review</jats:title> <jats:p>BRAF/MEK inhibitor has changed the treatment landscape in patients with advanced and metastatic melanoma with prolonged overall survival and progression-free survival. Since three treatment combinations exist with similar efficacy therapy decisions are often made based on the side effect profile. Additionally, on-target side effects or class effects have to be properly managed to ensure treatment adherence.</jats:p> </jats:sec> <jats:sec> <jats:title>Recent findings</jats:title> <jats:p>Sequential treatment with BRAF/MEK inhibition and immunotherapy might increase toxicity with a sepsis-like syndrome and triple therapy with concomitant BRAF/MEK inhibition and anti-PD1/PD-L1 antibody therapy induces severe side effects in the vast majority of patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Summary</jats:title> <jats:p>Toxicity of combination therapy with BRAF/MEK inhibitors is generally manageable, reversible and infrequently associated with treatment discontinuation. In case of persisting off-target effects the change to another combination therapy can resolve side effects.</jats:p> </jats:sec>
  • Description: <jats:sec>
    <jats:title>Purpose of review</jats:title>
    <jats:p>BRAF/MEK inhibitor has changed the treatment landscape in patients with advanced and metastatic melanoma with prolonged overall survival and progression-free survival. Since three treatment combinations exist with similar efficacy therapy decisions are often made based on the side effect profile. Additionally, on-target side effects or class effects have to be properly managed to ensure treatment adherence.</jats:p>
    </jats:sec>
    <jats:sec>
    <jats:title>Recent findings</jats:title>
    <jats:p>Sequential treatment with BRAF/MEK inhibition and immunotherapy might increase toxicity with a sepsis-like syndrome and triple therapy with concomitant BRAF/MEK inhibition and anti-PD1/PD-L1 antibody therapy induces severe side effects in the vast majority of patients.</jats:p>
    </jats:sec>
    <jats:sec>
    <jats:title>Summary</jats:title>
    <jats:p>Toxicity of combination therapy with BRAF/MEK inhibitors is generally manageable, reversible and infrequently associated with treatment discontinuation. In case of persisting off-target effects the change to another combination therapy can resolve side effects.</jats:p>
    </jats:sec>
  • Footnote: